Welcome to our dedicated page for TriSalus Life Sciences news (Ticker: TLSI), a resource for investors and traders seeking the latest updates and insights on TriSalus Life Sciences stock.
TriSalus Life Sciences, Inc. develops oncology-focused drug-delivery technology and an investigational immunotherapy program for solid tumors. Its Pressure-Enabled Drug Delivery, or PEDD, platform is used through the TriNav Infusion System in interventional radiology procedures, including TARE and TACE, for primary liver cancer and liver metastases.
Company news centers on TriNav commercial performance, clinical and preclinical data for PEDD, studies in liver tumors, research involving nelitolimod, and presentations to interventional radiology audiences. Updates also include quarterly financial results, revenue guidance, capital actions, shareholder voting matters and governance changes tied to the company’s oncology technology strategy.
TriSalus (Nasdaq: TLSI) reported strong commercial growth in Q4 2025 with $13.2M revenue (+60% y/y) and full-year $45.2M revenue (+53% y/y). The company raised $46M gross proceeds in a public offering, improved adjusted EBITDA, and reaffirmed 2026 revenue guidance of $60–62M.
Management cited product launches, expanded TriNav adoption, and planned commercial investments to support 2026 growth and broader PEDD platform adoption.
TriSalus Life Sciences (Nasdaq: TLSI) will host a conference call and webcast on Thursday, March 5, 2026 at 4:30 PM Eastern to discuss financial results for the quarter ended December 31, 2025. A press release with results will be issued before the call.
Participants can register for phone access and the webcast; a replay will be available on the investor relations website after the event.
TriSalus Life Sciences (Nasdaq: TLSI) priced an underwritten public offering of 9,756,100 common shares at $4.10 per share, with gross proceeds of approximately $40.0 million.
The company granted the underwriter a 30-day option to purchase up to 1,463,415 additional shares (15%). The offering is expected to close on or about February 23, 2026, subject to customary closing conditions.
TriSalus Life Sciences (Nasdaq: TLSI) announced its intent to sell shares of common stock in an underwritten public offering, with all shares to be sold by the company. TriSalus intends to grant underwriters a 30-day option to purchase up to 15% of the offering.
Lake Street Capital Markets is the sole book-runner. The offering is made from an effective Form S-3 shelf registration (File No. 333-291509) declared effective December 4, 2025, and is subject to market conditions; final terms will be disclosed in a prospectus supplement.
TriSalus Life Sciences (Nasdaq: TLSI) announced a board change effective February 4, 2026: Dr. Arjun “JJ” Desai resigned and Michael P. Stansky was appointed to the Board.
Mr. Stansky brings 40 years of investment and healthcare experience, prior roles at Tudor Investment and Wellington, current board seats at Insightec and Momentis Surgical, and credentials as a CPA and CFA.
TriSalus Life Sciences (Nasdaq: TLSI) reported preliminary unaudited results for Q4 and full-year 2025. Q4 2025 revenue was approximately $13.2 million (≈60% YoY) and full-year 2025 revenue was approximately $45.2 million (≈53% YoY), exceeding 2025 guidance. Year-end cash and cash equivalents were approximately $20.4 million, down $2.3 million from the start of Q4. The company set initial 2026 revenue guidance of approximately $60–$62 million. Results are preliminary, unaudited and subject to change pending year-end close and audit.
TriSalus Life Sciences (Nasdaq: TLSI) will host a virtual key opinion leader event on December 15, 2025 at 2:00 PM ET to discuss the TriNav Infusion System and the company's Pressure-Enabled Delivery for Thyroid Artery Embolization (PED-TAE) approach.
Juan C. Camacho, MD, will join company management to review the unmet need and current treatment landscape for symptomatic thyroid disease, explain how PED-TAE targets inferior thyroid arteries to reduce gland size and relieve symptoms for patients ineligible for surgery or conventional therapies, and answer questions from attendees.
TriSalus Life Sciences (NASDAQ: TLSI) reported $11.6 million revenue for Q3 2025, up 57% YoY and +3% sequentially, driven by TriNav sales in liver-directed applications. Gross margin was 84% versus 86% a year earlier. The company reduced quarterly cash burn by ~50% QoQ and held $22.7 million in cash and equivalents as of September 30, 2025, with reported adjusted EBITDA losses of $5.4 million (improved from $7.2M). Net loss attributable to common stockholders was $41.3 million, largely reflecting preferred-to-common conversion effects. TriSalus reaffirmed 2025 revenue guidance of at least 50% growth and highlighted clinical and investigator-published data for new embolization uses.
TriSalus Life Sciences (Nasdaq: TLSI) said CEO Mary Szela and CFO David Patience will attend investor conferences in November and December 2025. Management will hold one-on-one meetings and deliver corporate overviews at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Nov 20, 2025 at 2:30 PM ET, and at the 37th Annual Piper Healthcare Conference on Dec 2, 2025 at 3:10 PM ET. Live webcasts will be available, and a webcast replay will be posted for 90 days in the Events section of the TriSalus investor website at www.investors.trisaluslifesci.com.
TriSalus Life Sciences (Nasdaq: TLSI) will host a virtual key opinion leader event on November 12, 2025 at 10:00 AM ET to discuss uterine fibroids and the TriNav Infusion System.
Speakers Nicole Lamparello, MD and Francis Kang, MD will join company management to review the unmet need, current treatment landscape, the Uterine Artery Embolization (UAE) market opportunity, and an overview of the TriNav system with its Pressure-Enabled Drug Delivery™ (PEDD™) approach. A live Q&A will follow the presentations.